Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 65 publications
Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance Study.
Journal: The Journal of urology
Published: April 30, 2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial.
Journal: European urology
Published: April 23, 2025
Prostate Cancer Imaging Stewardship: a multimodal, physician-centered intervention for guideline-concordant imaging.
Journal: Journal of the National Cancer Institute
Published: March 14, 2025
Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study.
Journal: Journal of the National Cancer Institute
Published: February 04, 2025
Distinct Metabolomic Alterations Are Associated With Physical Function, Weight Loss, and Muscle Mass in Men With Cancer.
Journal: Journal of cachexia, sarcopenia and muscle
Published: January 27, 2025
Muscle mitochondria, function, mass, and quality of life in prostate cancer during androgen deprivation therapy.
Journal: Nature communications
Published: January 21, 2025
Effects of acute exercise on inflammatory and metabolic biomarkers in women: a randomized controlled trial.
Journal: NPJ breast cancer
Published: December 03, 2024
Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
Journal: JAMA
Published: May 30, 2024
The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance.
Journal: Cancer
Published: July 29, 2023
Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study.
Journal: Nutrition and cancer
Published: November 07, 2022
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
Journal: Clinical genitourinary cancer
Published: September 12, 2022
Last Updated: 09/26/2026